{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:58:30Z","timestamp":1792166310170,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515030028"],"award-info":[{"award-number":["2023A1515030028"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["JCYJ20220818100806015"],"award-info":[{"award-number":["JCYJ20220818100806015"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2019YFA0906100"],"award-info":[{"award-number":["2019YFA0906100"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41417-025-00872-1","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T22:57:59Z","timestamp":1737413879000},"page":"227-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CRISPR knock-in of a chimeric antigen receptor into GAPDH 3\u2019UTR locus generates potent B7H3-specific NK-92MI cells"],"prefix":"10.1038","volume":"32","author":[{"given":"Liujiang","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixia","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabiatu Bako","family":"Suleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8930-5262","authenticated-orcid":false,"given":"Guizhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3745-1860","authenticated-orcid":false,"given":"Xiaochun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"872_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02420-8","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Rahman HS, Al-Obaidi ZMJ, Jalil AT, Abdelbasset WK, Suksatan W, et al. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Res Ther. 2021;12:1\u201323.","journal-title":"Stem Cell Res Ther"},{"key":"872_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619:707\u201315.","journal-title":"Nature"},{"key":"872_CR3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724\u201340.","journal-title":"Cell"},{"key":"872_CR4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201529","volume":"218","author":"R-S Huang","year":"2021","unstructured":"Huang R-S, Lai M-C, Shih H-A, Lin S. A robust platform for expansion and genome editing of primary human natural killer cells. J Exp Med. 2021;218:e20201529.","journal-title":"J Exp Med"},{"key":"872_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fimmu.2017.00465","volume":"8","author":"F Simonetta","year":"2017","unstructured":"Simonetta F, Alvarez M, Negrin RS. Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation. Front Immunol. 2017;8:465.","journal-title":"Front Immunol"},{"key":"872_CR6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1089\/hum.2012.080","volume":"23","author":"T Sutlu","year":"2012","unstructured":"Sutlu T, Nystr\u00f6m S, Gilljam M, Stellan B, Applequist SE, Alici E. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Hum Gene Ther. 2012;23:1090\u20131100.","journal-title":"Hum Gene Ther"},{"key":"872_CR7","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","volume":"112","author":"M Liu","year":"2022","unstructured":"Liu M, Huang W, Guo Y, Zhou Y, Zhi C, Chen J, et al. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo. J Leukocyte Biol. 2022;112:901\u201311.","journal-title":"J Leukocyte Biol"},{"key":"872_CR8","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8:1083.","journal-title":"Am J Cancer Res"},{"key":"872_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.omtm.2021.01.008","volume":"20","author":"DS Allan","year":"2021","unstructured":"Allan DS, Chakraborty M, Waller GC, Hochman MJ, Poolcharoen A, Reger RN, et al. Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion. Mol Ther Methods Clin Dev. 2021;20:559\u201371.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"872_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307\u201312.","journal-title":"Nature"},{"key":"872_CR11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41551-019-0409-0","volume":"3","author":"K Schober","year":"2019","unstructured":"Schober K, M\u00fcller TR, G\u00f6kmen F, Grassmann S, Effenberger M, Poltorak M, et al. Orthotopic replacement of T-cell receptor \u03b1-and \u03b2-chains with preservation of near-physiological T-cell function. Nat Biomed Eng. 2019;3:974\u201384.","journal-title":"Nat Biomed Eng"},{"key":"872_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","volume":"3","author":"MJ Frigault","year":"2015","unstructured":"Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol. Res. 2015;3:356\u201367.","journal-title":"Cancer Immunol. Res"},{"key":"872_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207394","volume":"10","author":"C Liao","year":"2023","unstructured":"Liao C, Wang Y, Huang Y, Duan Y, Liang Y, Chen J, et al. CD38\u2010specific CAR integrated into CD38 locus driven by different promoters causes distinct antitumor activities of T and NK cells. Adv Sci. 2023;10:2207394.","journal-title":"Adv Sci"},{"key":"872_CR14","doi-asserted-by":"publisher","first-page":"9874","DOI":"10.1021\/acs.chemrev.6b00799","volume":"117","author":"H-X Wang","year":"2017","unstructured":"Wang H-X, Li M, Lee CM, Chakraborty S, Kim H-W, Bao G, et al. CRISPR\/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem Rev. 2017;117:9874\u2013906.","journal-title":"Chem Rev"},{"key":"872_CR15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity. science. 2012;337:816\u201321.","journal-title":"science"},{"key":"872_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR\/Cas systems. Science. 2013;339:819\u201323.","journal-title":"Science"},{"key":"872_CR17","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823\u20136.","journal-title":"Science"},{"key":"872_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature13589","volume":"514","author":"W Xue","year":"2014","unstructured":"Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014;514:380\u20134.","journal-title":"Nature"},{"key":"872_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nbt.2884","volume":"32","author":"H Yin","year":"2014","unstructured":"Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 2014;32:551\u20133.","journal-title":"Nat. Biotechnol"},{"key":"872_CR20","doi-asserted-by":"crossref","unstructured":"Guo C, et al. CBLB, CISH and CD70 multiplexed gene knockout with CRISPR\/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-\u03b2 for cancer immunotherapy. Cancer Res. 2022;82:5512.","DOI":"10.1158\/1538-7445.AM2022-5512"},{"key":"872_CR21","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1182\/blood-2022-169758","volume":"140","author":"N Albinger","year":"2022","unstructured":"Albinger N, Bexte T, Buchinger L, Wendel P, Al-Ajami A, Gessner A, et al. CRISPR\/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-CAR-NK cells against AML. Blood. 2022;140:4558\u20139.","journal-title":"Blood"},{"key":"872_CR22","doi-asserted-by":"crossref","unstructured":"Navin I, Dysthe M, Baumgartner C. Parihar R 413 Genetic deletion of TIGIT enhances CAR-NK cell function in the solid tumor microenvironment. BMJ Specialist J. 2022;10:2.","DOI":"10.1136\/jitc-2022-SITC2022.0413"},{"key":"872_CR23","doi-asserted-by":"crossref","unstructured":"Guo X, Mahlak\u00f5iv T, Ye Q, Somanchi S, He S, Rana H, et al. CBLB ablation with CRISPR\/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy. J Immunother Cancer. 2021;9:e001975.","DOI":"10.1136\/jitc-2020-001975"},{"key":"872_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543:113\u20137.","journal-title":"Nature"},{"key":"872_CR25","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/nprot.2006.207","volume":"1","author":"JC Grieger","year":"2006","unstructured":"Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc. 2006;1:1412\u201328.","journal-title":"Nat Protoc."},{"key":"872_CR26","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25:2560\u201374.","journal-title":"Clin Cancer Res."},{"key":"872_CR27","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman EK, Chen T, Amendola M, Van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acid Res. 2014;42:e168.","journal-title":"Nucleic Acid Res"},{"key":"872_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","volume":"35","author":"S Bournazos","year":"2017","unstructured":"Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Signaling by antibodies: recent progress. Annu Rev Immunol. 2017;35:285\u2013311.","journal-title":"Annu Rev Immunol"},{"key":"872_CR29","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1073\/pnas.96.10.5640","volume":"96","author":"O Mandelboim","year":"1999","unstructured":"Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci USA. 1999;96:5640\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"872_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"key":"872_CR31","doi-asserted-by":"publisher","first-page":"111299","DOI":"10.1016\/j.biopha.2021.111299","volume":"137","author":"Z Wu","year":"2021","unstructured":"Wu Z, Zhang H, Wu M, Peng G, He Y, Wan N, et al. Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia. Biomed Pharmacother. 2021;137:111299.","journal-title":"Biomed Pharmacother"},{"key":"872_CR32","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","volume":"13","author":"R Dienstmann","year":"2014","unstructured":"Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13:1021\u201331.","journal-title":"Mol Cancer Ther"},{"key":"872_CR33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","volume":"28","author":"KD Courtney","year":"2010","unstructured":"Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncology. 2010;28:1075.","journal-title":"J Clin Oncology"},{"key":"872_CR34","doi-asserted-by":"crossref","unstructured":"Nicholls C, Li H, Liu J-P. GAPDH: A common enzyme with uncommon functions. Clin Exp Pharmacol Physiol. 2012;39:674\u20139.","DOI":"10.1111\/j.1440-1681.2011.05599.x"},{"key":"872_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3389\/fimmu.2015.00355","volume":"6","author":"AK Ali","year":"2015","unstructured":"Ali AK, Nandagopal N, Lee S-H. IL-15\u2013PI3K\u2013AKT\u2013mTOR: a critical pathway in the life journey of natural killer cells. Front Immunol. 2015;6:355.","journal-title":"Front Immunol."},{"key":"872_CR36","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s41375-023-01948-3","volume":"37","author":"J Jiang","year":"2023","unstructured":"Jiang J, Chen J, Liao C, Duan Y, Wang Y, Shang K, et al. Inserting EF1\u03b1-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia. 2023;37:1660\u201370.","journal-title":"Leukemia"},{"key":"872_CR37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s42003-023-04978-w","volume":"6","author":"SP Fraessle","year":"2023","unstructured":"Fraessle SP, Tschulik C, Effenberger M, Cletiu V, Gerget M, Schober K, et al. Activation-inducible CAR expression enables precise control over engineered CAR T cell function. Commun Biol. 2023;6:604.","journal-title":"Commun Biol"},{"key":"872_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.bbagrm.2007.10.004","volume":"1779","author":"L Malquori","year":"2008","unstructured":"Malquori L, Carsetti L, Ruberti G. The 3\u2032 UTR of the human CTLA4 mRNA can regulate mRNA stability and translational efficiency. Biochim Biophys Acta (BBA)-Gene Reg Mech. 2008;1779:60\u201365.","journal-title":"Biochim Biophys Acta (BBA)-Gene Reg Mech"},{"key":"872_CR39","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.molcel.2016.02.027","volume":"61","author":"Y Mishima","year":"2016","unstructured":"Mishima Y, Tomari Y. Codon usage and 3\u2032 UTR length determine maternal mRNA stability in zebrafish. Mol Cell. 2016;61:874\u201385.","journal-title":"Mol Cell"},{"key":"872_CR40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.molcel.2014.05.022","volume":"55","author":"M Yokoshi","year":"2014","unstructured":"Yokoshi M, Li Q, Yamamoto M, Okada H, Suzuki Y, Kawahara Y. Direct binding of Ataxin-2 to distinct elements in 3\u2032 UTRs promotes mRNA stability and protein expression. Mol Cell. 2014;55:186\u201398.","journal-title":"Mol Cell"},{"key":"872_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2016.e00080","volume":"2","author":"R Yamaguchi","year":"2016","unstructured":"Yamaguchi R, Yamamoto T, Sakamoto A, Ishimaru Y, Narahara S, Sugiuchi H, et al. Roles of myeloperoxidase and GAPDH in interferon-gamma production of GM-CSF-dependent macrophages. Heliyon. 2016;2:e00080.","journal-title":"Heliyon"},{"key":"872_CR42","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.molcel.2023.12.015","volume":"84","author":"X Wang","year":"2024","unstructured":"Wang X, Fu SQ, Yuan X, Yu F, Ji Q, Tang HW, et al. A GAPDH serotonylation system couples CD8(+) T cell glycolytic metabolism to antitumor immunity. Mol Cell. 2024;84:760\u2013775.e7.","journal-title":"Mol Cell"},{"key":"872_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","volume":"7","author":"H Klingemann","year":"2016","unstructured":"Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy\u2013advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016;7:91.","journal-title":"Front Immunol"},{"key":"872_CR44","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","volume":"21","author":"A Page","year":"2024","unstructured":"Page A, Chuvin N, Valladeau-Guilemond J, Depil S. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol. 2024;21:315\u201331.","journal-title":"Cell Mol Immunol."}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00872-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00872-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00872-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:54:31Z","timestamp":1739962471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00872-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00872-1","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies involving human participants. All animal procedures were approved by the institutional animal care and use committee (IACUC) of Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}